Renal cell carcinoma bone metastasis-elucidating the molecular targets

Kristy Weber, Michele Doucet, Scott Kominsky

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


The development of bone metastasis from renal cell carcinoma (RCC) signals a transition to a terminal state for the patient with previously isolated disease. These patients may suffer the morbidity of severe, persistent pain, pathologic fractures, and spinal compression from vertebral metastasis before they succumb to their cancer. Although recent advancements have been made in the understanding of breast and prostate bone metastasis, there has been less knowledge in the area of metastatic RCC to the skeleton. This particular cancer in bone remains relatively resistant to standard forms of treatment such as radiation and chemotherapy. A better understanding of the biology of RCC bone metastasis is critically needed in order to improve treatment. Bone-derived cell lines and an experimental animal model have been developed in order to explore the relevant mechanisms of how RCC cells survive within and destroy the bone. This review will focus on the growth factor signaling pathways most important for the RCC-stimulated osteoclast-mediated bone destruction, namely the epidermal growth factor receptor (EGF-R) and transforming growth factor-β receptor (TGF-βR) pathways. By inhibiting these receptors, growth of RCC within the bone is decreased which, directly or indirectly, decreases bone destruction.

Original languageEnglish (US)
Pages (from-to)691-704
Number of pages14
JournalCancer and Metastasis Reviews
Issue number3-4
StatePublished - Dec 2007


  • Bone
  • Growth factors
  • Metastasis
  • Mouse model
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Renal cell carcinoma bone metastasis-elucidating the molecular targets'. Together they form a unique fingerprint.

Cite this